专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008145688A3 PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS 审中-公开
公开(公告)号：WO2008145688A3
公开(公告)日：2008-12-04
申请号：PCT/EP2008/056597
申请日：2008-05-29
申请人： GLAXO GROUP LIMITED , BAMBOROUGH, Paul , BARKER, Michael, David , CAMPOS, Sebastien, Andre , COUSINS, Richard, Peter, Charles , FAULDER, Paul , HOBBS, Heather , HOLMES, Duncan, Stuart , JOHNSTON, Michael, John , LIDDLE, John , PAYNE, Jeremy, John , PRITCHARD, John, Martin , WHITWORTH, Caroline
发明人： BAMBOROUGH, Paul , BARKER, Michael, David , CAMPOS, Sebastien, Andre , COUSINS, Richard, Peter, Charles , FAULDER, Paul , HOBBS, Heather , HOLMES, Duncan, Stuart , JOHNSTON, Michael, John , LIDDLE, John , PAYNE, Jeremy, John , PRITCHARD, John, Martin , WHITWORTH, Caroline
IPC分类号： C07D471/04 , A61K31/437 , A61P19/02 , A61P29/00 , A61P11/06
摘要： The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.

2. 发明申请

WO2008034860A1 PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS 审中-公开
标题翻译：吡咯并[2,3-B]吡啶-4-基 - 苯甲酰胺化合物作为IKK2抑制剂
公开(公告)号：WO2008034860A1
公开(公告)日：2008-03-27
申请号：PCT/EP2007/059933
申请日：2007-09-20
申请人： GLAXO GROUP LIMITED , BAMBOROUGH, Paul , BARKER, Michael, David , CAMPOS, Sebastien, Andre , COUSINS, Richard, Peter, Charles , FAULDER, Paul , HOBBS, Heather , HOLMES, Duncan, Stuart , JOHNSTON, Michael, John , LIDDLE, John , PAYNE, Jeremy, John , PRITCHARD, John, Martin , WHITWORTH, Caroline
发明人： BAMBOROUGH, Paul , BARKER, Michael, David , CAMPOS, Sebastien, Andre , COUSINS, Richard, Peter, Charles , FAULDER, Paul , HOBBS, Heather , HOLMES, Duncan, Stuart , JOHNSTON, Michael, John , LIDDLE, John , PAYNE, Jeremy, John , PRITCHARD, John, Martin , WHITWORTH, Caroline
IPC分类号： C07D471/04 , A61K31/437 , A61P29/00
CPC分类号： C07D471/04
摘要： The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
摘要翻译：本发明涉及某些新化合物。具体地，本发明涉及式（I）化合物及其盐。本发明的化合物是激酶活性的抑制剂，特别是IKK2活性。

3. 发明申请

WO2004016578A3 ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS 审中-公开
标题翻译：氨基乙酰胺BETA2-腺苷二磷酸激动剂化合物
公开(公告)号：WO2004016578A3
公开(公告)日：2004-06-10
申请号：PCT/EP0308264
申请日：2003-07-24
申请人： GLAXO GROUP LTD , BIGGADIKE KEITH , COE DIANE MARY , HOLMES DUNCAN STUART , LOOKER BRIAN EDGAR
发明人： BIGGADIKE KEITH , COE DIANE MARY , HOLMES DUNCAN STUART , LOOKER BRIAN EDGAR
IPC分类号： C07D215/24 , A61K31/18 , A61K31/428 , A61K31/44 , A61K31/4704 , A61K31/538 , A61P11/00 , A61P11/06 , A61P11/08 , A61P25/02 , C07C303/40 , C07C311/29 , C07C311/37 , C07D213/65 , C07D215/26 , C07D265/36 , C07D277/68 , C07C217/10 , C07C213/00
CPC分类号： C07D277/68 , C07C311/29 , C07D213/65 , C07D215/26 , C07D265/36
摘要： The present invention concerns compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, wherein: R is hydrogen or -XSO2NR R ; R and R are independently selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, halo, phenyl and C1-6 haloalkyl and Ar is a group selected from and. Processes for preparing said compounds and pharmaceutical formulations containing them are also described. Compounds of formula (I) are useful in the treatment of respiratory diseases
摘要翻译：本发明涉及式（I）化合物及其盐，溶剂化物和生理功能衍生物，其中：R 1是氢或-XSO 2 NR 6 R 7; R 2和R 3独立地选自氢，C 1-6烷基，C 1-6烷氧基，卤素，苯基和C 1-6卤代烷基，Ar是选自和。还描述了制备所述化合物的方法和含有它们的药物制剂。式（I）化合物可用于治疗呼吸系统疾病

4. 发明申请

WO2004016578A2 MEDICINAL COMPOUNDS 审中-公开
标题翻译：药物化合物
公开(公告)号：WO2004016578A2
公开(公告)日：2004-02-26
申请号：PCT/EP2003/008264
申请日：2003-07-24
申请人： GLAXO GROUP LIMITED , BIGGADIKE, Keith , COE, Diane, Mary , HOLMES, Duncan, Stuart , LOOKER, Brian, Edgar
发明人： COE, Diane, Mary , HOLMES, Duncan, Stuart , LOOKER, Brian, Edgar
IPC分类号： C07C217/10
CPC分类号： C07D277/68 , C07C311/29 , C07D213/65 , C07D215/26 , C07D265/36
摘要： The present invention concerns compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, wherein: R 1 is hydrogen or -XSO 2 NR 6 R 7 ; R 2 and R 3 are independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, halo, phenyl and C 1-6 haloalkyl and Ar is a group selected from and. Processes for preparing said compounds and pharmaceutical formulations containing them are also described. Compounds of formula (I) are useful in the treatment of respiratory diseases
摘要翻译：本发明涉及式（I）化合物及其盐，溶剂化物和生理功能衍生物，其中：R 1是氢或-XSO 2 NR 6 R 7; R 2和R 3独立地选自氢，C 1-6烷基，C 1-6烷氧基，卤素，苯基和C 1-6卤代烷基，Ar是选自和。还描述了制备所述化合物的方法和含有它们的药物制剂。式（I）化合物可用于治疗呼吸系统疾病

5. 发明申请

WO2008145688A2 NOVEL COMPOUNDS 审中-公开
标题翻译：新型化合物
公开(公告)号：WO2008145688A2
公开(公告)日：2008-12-04
申请号：PCT/EP2008056597
申请日：2008-05-29
申请人： GLAXO GROUP LTD , BAMBOROUGH PAUL , BARKER MICHAEL DAVID , CAMPOS SEBASTIEN ANDRE , COUSINS RICHARD PETER CHARLES , FAULDER PAUL , HOBBS HEATHER , HOLMES DUNCAN STUART , JOHNSTON MICHAEL JOHN , LIDDLE JOHN , PAYNE JEREMY JOHN , PRITCHARD JOHN MARTIN , WHITWORTH CAROLINE
发明人： BAMBOROUGH PAUL , BARKER MICHAEL DAVID , CAMPOS SEBASTIEN ANDRE , COUSINS RICHARD PETER CHARLES , FAULDER PAUL , HOBBS HEATHER , HOLMES DUNCAN STUART , JOHNSTON MICHAEL JOHN , LIDDLE JOHN , PAYNE JEREMY JOHN , PRITCHARD JOHN MARTIN , WHITWORTH CAROLINE
IPC分类号： C07D471/04 , A61K31/437 , A61P11/06 , A61P19/02 , A61P29/00
CPC分类号： C07D471/04
摘要： The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
摘要翻译：本发明涉及某些新化合物。具体地，本发明涉及式（I）化合物及其盐。本发明的化合物是激酶活性的抑制剂，特别是IKK2活性。

6. 发明申请

WO2004016578A8 ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS 审中-公开
标题翻译：氨基乙酰胺BETA2-腺苷二磷酸激动剂化合物
公开(公告)号：WO2004016578A8
公开(公告)日：2005-02-17
申请号：PCT/EP0308264
申请日：2003-07-24
申请人： GLAXO GROUP LTD , BIGGADIKE KEITH , COE DIANE MARY , HOLMES DUNCAN STUART , LOOKER BRIAN EDGAR
发明人： BIGGADIKE KEITH , COE DIANE MARY , HOLMES DUNCAN STUART , LOOKER BRIAN EDGAR
IPC分类号： C07D215/24 , A61K31/18 , A61K31/428 , A61K31/44 , A61K31/4704 , A61K31/538 , A61P11/00 , A61P11/06 , A61P11/08 , A61P25/02 , C07C303/40 , C07C311/29 , C07C311/37 , C07D213/65 , C07D215/26 , C07D265/36 , C07D277/68 , C07C217/10 , C07C213/00
CPC分类号： C07D277/68 , C07C311/29 , C07D213/65 , C07D215/26 , C07D265/36
摘要： The present invention concerns compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, wherein: R is hydrogen or -XSO2NR R ; R and R are independently selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, halo, phenyl and C1-6 haloalkyl and Ar is a group selected from and. Processes for preparing said compounds and pharmaceutical formulations containing them are also described. Compounds of formula (I) are useful in the treatment of respiratory diseases
摘要翻译：本发明涉及式（I）化合物及其盐，溶剂化物和生理功能衍生物，其中：R 1是氢或-XSO 2 NR 6 R 7; R 2和R 3独立地选自氢，C 1-6烷基，C 1-6烷氧基，卤素，苯基和C 1-6卤代烷基，Ar是选自和。还描述了制备所述化合物的方法和含有它们的药物制剂。式（I）化合物可用于治疗呼吸系统疾病

7. 发明申请

WO2004039766A1 PHENYLETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES 审中-公开
标题翻译：用于治疗呼吸道疾病的苯乙醇胺衍生物
公开(公告)号：WO2004039766A1
公开(公告)日：2004-05-13
申请号：PCT/EP2003/012161
申请日：2003-10-30
申请人： GLAXO GROUP LIMITED , BIGGADIKE, Keith , BLAKE, Keith , COE, Diane, Mary , HOLMES, Duncan, Stuart , PROCOPIOU, Panayiotis, Alexandrou
发明人： BIGGADIKE, Keith , BLAKE, Keith , COE, Diane, Mary , HOLMES, Duncan, Stuart , PROCOPIOU, Panayiotis, Alexandrou
IPC分类号： C07C275/28
CPC分类号： C07D213/75 , C07C275/32 , C07D213/63
摘要： The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.
摘要翻译：本发明涉及式（I）的新化合物，其制备方法，含有它们的药物组合物及其在治疗中的用途，特别是其在预防和治疗呼吸系统疾病中的用途。

8. 发明申请

WO1993001174A1 THIAZOLIDINE DERIVATIVES AND THEIR USE AS ANTI-VIRAL COMPOUNDS 审中-公开
标题翻译：噻唑烷衍生物及其作为抗病毒化合物的用途
公开(公告)号：WO1993001174A1
公开(公告)日：1993-01-21
申请号：PCT/EP1992001494
申请日：1992-07-03
申请人： GLAXO GROUP LIMITED , KITCHIN, John , HOLMES, Duncan, Stuart , HUMBER, David, Cedric , STORER, Richard , DOLAN, Simon, Charles , HANN, Michael, Menteith , MCMEEKIN, Peter , MURRAY-RUST, Peter , PATEL, Binakumari , WEINGARTEN, Gordon, Gad
发明人： GLAXO GROUP LIMITED
IPC分类号： C07D217/06
CPC分类号： C07D417/12 , C07D277/06 , C07D417/14
摘要： The present invention provides compounds of formula (I), wherein R is hydrogen, alkyl or CH2alkyl where the alkyl portion is substituted by OH; A represents either a group CHR CHR OH or a group (II), where R is hydrogen, alkyl, cycloalkylalkyl or Aralkyl, R is hydrogen, alkyl, cycloalkylalkyl, aralkyl, CHR CONR R (where R is hydrogen, alkyl, cycloalkylalkyl or Aralkyl, R is hydrogen or methyl and R is hydrogen, alkyl optionnally substituted by one or two hydroxyl groups, aryl, heteroaryl, cycloalkylalkyl, Aralkyl wherein the alkyl portion is optionnally substituted by hydroxymethyl, or Hetalkyl) or CHR NHCOR (where R is alkyl, cycloalkylalkyl or an aralkyl), R is alkoxy or NR R (where R is hydrogen or methyl and R is hydrogen, alkyl, aryl, aralkyl or cycloalkylalkyl); X is a group -CHR (CHR )r(CHR )sCHR -, where R and R are hydrogen, r is 1, s is zero and R is hydroxyl or hydroxymethyl, or R and R are hydrogen, r and s are 1 and R and R are each hydrogen or hydroxyl provided that at least one of R and R is hydroxyl, or one of R and R is hydrogen and the other is hydroxymethyl and r and s are zero; useful in chemotherapy, particularly of viral infections.
摘要翻译：本发明提供式（I）化合物，其中R 1是氢，烷基或C 2烷基，其中烷基部分被OH取代; A代表基团CHR 21 CHR 22 OH或基团（II），其中R 21是氢，烷基，环烷基烷基或芳烷基，R 22是氢，烷基，环烷基烷基，芳烷基，CHR 24 R CONR 25 R 26（其中R 24是氢，烷基，环烷基烷基或芳烷基，R 25是氢或甲基，R 26是氢，烷基选择性地被一个或两个羟基取代，芳基，杂芳基，环烷基烷基，芳烷基，其中烷基部分选择性地被羟甲基或Hetalkyl取代）或CHR 24 NHCOR 27（其中R 27是烷基，环烷基烷基或芳烷基），R 23是烷氧基或NR 28 R 29（其中R 28是氢或甲基，R 29是氢，烷基，芳基，芳烷基或环烷基烷基）; X是基团-CHR 30（CHR 31）r（CHR 32）s CHR 33，其中R 30和R 33是氢，r是1，s是0，R 31是羟基或羟甲基，或R 30和R 33是氢，r和s是1，R 31和R 32各自是氢或羟基，条件是R 31中至少有一个且R 32为羟基，R 30和R 33之一为氢，另一个为羟甲基，r和s为0; 可用于化疗，特别是病毒感染。

9. 发明申请

WO2004071388A3 MEDICINAL COMPOUNDS 审中-公开
标题翻译：药物化合物
公开(公告)号：WO2004071388A3
公开(公告)日：2005-01-06
申请号：PCT/EP2004001415
申请日：2004-02-12
申请人： GLAXO GROUP LTD , BIGGADIKE KEITH , BOX PHILIP CHARLES , COE DIANE MARY , HOLMES DUNCAN STUART , LOOKER BRIAN EDGAR , PROCOPIOU PANAYIOTIS ALEXANDRO
发明人： BIGGADIKE KEITH , BOX PHILIP CHARLES , COE DIANE MARY , HOLMES DUNCAN STUART , LOOKER BRIAN EDGAR , PROCOPIOU PANAYIOTIS ALEXANDRO
IPC分类号： A61K20060101 , A61K31/136 , A61K31/167 , A61K31/18 , A61K31/44 , A61P11/06 , C07C217/08 , C07C217/28 , C07C233/43 , C07C311/13 , C07D213/65
CPC分类号： C07D213/65 , C07C217/28
摘要： A compound of formula (I) or a salt, solvate, or physiologically functional derivative thereof, wherein: m is an integer of from 2 to 8; n is an integer of from 2 to 5; with the proviso that m + n is 4 to 10; R and R are independently selected from hydrogen and C1-4 alkyl with the proviso that the total number of carbon atoms in R and R is not more than 4; R and R are independently selected from hydrogen and C1-4alkyl with the proviso that the total number of carbon atoms in R and R is not more than 4, and Ar is a group selected from (a), (b), (c) and (d).
摘要翻译：式（I）化合物或其盐，溶剂合物或生理功能衍生物，其中：m为2至8的整数; n为2〜5的整数，条件是m + n为4至10; R 4和R 5独立地选自氢和C 1-4烷基，条件是R 4和R 5中的碳原子总数不大于4; R 6和R 7独立地选自氢和C 1-4烷基，条件是R 6和R 7中的碳原子总数不大于4，Ar 1是选自（a），（b），（c）和（d）的基团。

10. 发明申请

WO2004071388A2 MEDICINAL COMPOUNDS 审中-公开
标题翻译：药物化合物
公开(公告)号：WO2004071388A2
公开(公告)日：2004-08-26
申请号：PCT/EP2004/001415
申请日：2004-02-12
申请人： GLAXO GROUP LIMITED , BIGGADIKE, Keith , BOX, Philip, Charles , COE, Diane, Mary , HOLMES, Duncan, Stuart , LOOKER, Brian, Edgar , PROCOPIOU, Panayiotis, Alexandrou
发明人： BIGGADIKE, Keith , BOX, Philip, Charles , COE, Diane, Mary , HOLMES, Duncan, Stuart , LOOKER, Brian, Edgar , PROCOPIOU, Panayiotis, Alexandrou
IPC分类号： A61K
CPC分类号： C07D213/65 , C07C217/28
摘要： A compound of formula (I) or a salt, solvate, or physiologically functional derivative thereof, wherein: m is an integer of from 2 to 8; n is an integer of from 2 to 5; with the proviso that m + n is 4 to 10; R 4 and R 5 are independently selected from hydrogen and C 1-4 alkyl with the proviso that the total number of carbon atoms in R 4 and R 5 is not more than 4; R 6 and R 7 are independently selected from hydrogen and C 1-4 alkyl with the proviso that the total number of carbon atoms in R 6 and R 7 is not more than 4, and Ar 1 is a group selected from (a), (b), (c) and (d).
摘要翻译：式（I）化合物或其盐，溶剂合物或生理功能衍生物，其中：m为2至8的整数; n为2〜5的整数，条件是m + n为4至10; R 4和R 5独立地选自氢和C 1-4烷基，条件是R 4和R 5中的碳原子总数不大于4; R 6和R 7独立地选自氢和C 1-4烷基，条件是R 6和R 7中的碳原子总数不大于4，Ar 1是选自（a），（b），（c）和（d）的基团。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式